Cure My Disease

Don't miss your cure!

 Log in / Sign up

A tracer that lights up immune attack: can scans predict who responds to cancer immunotherapy?

NCT ID NCT07039474

Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 28, 2026 · Last updated Sep 29, 2026 · Updated 1 time

Summary

Researchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. The study checks whether the tracer is safe and whether its uptake in tumors, liver, lung, and kidney can predict which patients respond to immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-G1, a radioactive tracer that binds to granzyme B and is injected before PET/CT imaging
What this could lead to
If it works, doctors could use a PET/CT scan to tell early whether immunotherapy is helping a patient, so they can switch treatments sooner when it is not.
What could go wrong
The tracer is experimental and may not reliably light up tumors or predict response. The study is small and early, and scan results could miss the mark or vary between patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects diagnosed with a malignant tumor (solid tumor or hematological tumor) by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy).

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team. 2. Subjects didn't receive previous immunotherapy. 3. There exists at least one measurable target lesion according to the RECIST 1.1. 4. ECOG performance status≤2. 5. The expected survival time is ≥6 months. 6. Effective contraceptive measures will be adopted during the study period and within 6 months after the study. 7. Willing and able to fully understand and sign the informed consent form. Exclusion Criteria: 1. Women in the preconception period, pregnancy, or lactation period. 2. Combined with other malignant tumor. 3. Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy. 4. Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency. 5. Receiving radiotherapy or interventional therapy during the immunotherapy. 6. 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm kidney cancer lung cancer lung neoplasm lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Esophagus cancer Hematologic cancer Kidney cancer Lung cancer Lymphoma Solid tumor malignancies Stomach cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University First Hospital

    RECRUITING

    Beijing, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.